Rosalind Advisors
Latest statistics and disclosures from Rosalind Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DCTH, SVRA, FENC, XERS, VRDN, and represent 36.63% of Rosalind Advisors's stock portfolio.
- Added to shares of these 10 stocks: REPL (+$14M), AVBP, XFOR, FENC, PROF, XERS, OKUR, Anavex Life Sciences Corp put, Regentis Biomaterials, Powershares Qqq Etf Put Opt 01/19 154.0 put.
- Started 11 new stock positions in Arrivent Biopharma, AVBP, Viking Therapeutics Inc call, Replimune Group, Vistagen Therapeutics, REPL, Anavex Life Sciences Corp put, NRXS, Uniqure Nv call, OKUR. Regentis Biomaterials.
- Reduced shares in these 10 stocks: RZLT (-$17M), CYTK (-$13M), VRNA (-$11M), GUTS (-$10M), IDYA (-$9.5M), QURE (-$7.3M), VRDN, Atyr Pharma Inc put, SVRA, Astria Therapeutics.
- Sold out of its positions in Atyr Pharma Inc put, Astria Therapeutics, IDYA, Ideaya Biosciences, RZLT, Scholar Rock Hldg Corp, VRNA, QURE.
- Rosalind Advisors was a net seller of stock by $-42M.
- Rosalind Advisors has $285M in assets under management (AUM), dropping by -2.75%.
- Central Index Key (CIK): 0001622627
Tip: Access up to 7 years of quarterly data
Positions held by Rosalind Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rosalind Advisors
Rosalind Advisors holds 42 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Delcath Systems Com New (DCTH) | 11.6 | $33M | 3.3M | 10.00 |
|
|
| Savara (SVRA) | 7.2 | $21M | -14% | 3.4M | 6.03 |
|
| Fennec Pharmaceuticals (FENC) | 7.1 | $20M | +25% | 2.6M | 7.70 |
|
| Xeris Pharmaceuticals (XERS) | 5.8 | $17M | +17% | 2.1M | 7.85 |
|
| Miragen Therapeutics (VRDN) | 4.9 | $14M | -25% | 450k | 31.12 |
|
| Mediwound Shs New (MDWD) | 4.9 | $14M | 749k | 18.46 |
|
|
| Verastem Com New (VSTM) | 4.9 | $14M | -7% | 1.8M | 7.72 |
|
| Replimune Group (REPL) | 4.8 | $14M | NEW | 1.4M | 9.72 |
|
| Atyr Pharma (ATYR) | 4.8 | $14M | 1.0M | 13.09 |
|
|
| Cybin Com New (HELP) | 4.8 | $14M | +10% | 1.7M | 8.18 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 4.4 | $13M | +6% | 690k | 18.27 |
|
| Cg Oncology (CGON) | 4.4 | $13M | 300k | 41.52 |
|
|
| Cytokinetics Com New (CYTK) | 4.4 | $12M | -51% | 195k | 63.54 |
|
| X4 Pharmaceuticals Com New (XFOR) | 3.7 | $10M | +68% | 2.6M | 4.00 |
|
| Mind Medicine Mindmed Com New (MNMD) | 3.5 | $10M | 750k | 13.39 |
|
|
| Profound Medical Corp Com New (PROF) | 3.0 | $8.4M | +54% | 1.1M | 7.87 |
|
| Inspiremd (NSPR) | 2.4 | $7.0M | 3.9M | 1.78 |
|
|
| Ocular Therapeutix (OCUL) | 1.7 | $4.9M | 400k | 12.14 |
|
|
| Arrivent Biopharma (AVBP) | 1.5 | $4.3M | NEW | 216k | 20.12 |
|
| Talphera Com New (TLPH) | 1.4 | $4.1M | -18% | 3.6M | 1.14 |
|
| Myomo Com New (MYO) | 1.2 | $3.5M | 3.8M | 0.91 |
|
|
| Invesco Qqq Tr Put Put Option | 1.1 | $3.0M | +80% | 450k | 6.73 |
|
| Polypid (PYPD) | 1.1 | $3.0M | -24% | 697k | 4.34 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.7 | $2.1M | NEW | 731k | 2.90 |
|
| Spdr S&p 500 Etf Tr Put Put Option | 0.7 | $1.9M | +70% | 510k | 3.70 |
|
| Anavex Life Sciences Corp Put Put Option | 0.7 | $1.9M | NEW | 1.2M | 1.61 |
|
| Regentis Biomaterials Ordinary Shares | 0.6 | $1.7M | NEW | 252k | 6.74 |
|
| Spdr Series Trust Put Put Option | 0.5 | $1.3M | -8% | 1.9M | 0.70 |
|
| Trevi Therapeutics (TRVI) | 0.4 | $1.3M | 100k | 12.52 |
|
|
| Ishares Tr Put Put Option | 0.4 | $1.1M | 200k | 5.56 |
|
|
| Neuraxis (NRXS) | 0.4 | $1.0M | NEW | 286k | 3.63 |
|
| Kura Oncology (KURA) | 0.4 | $1.0M | 100k | 10.39 |
|
|
| Fractyl Health (GUTS) | 0.3 | $849k | -92% | 386k | 2.20 |
|
| Biofrontera Com New (BFRI) | 0.2 | $650k | 1.1M | 0.57 |
|
|
| Arrivent Biopharma Call Call Option | 0.2 | $540k | NEW | 108k | 5.00 |
|
| Verastem Call Call Option | 0.1 | $160k | -58% | 269k | 0.59 |
|
| Uniqure Nv Call Call Option | 0.0 | $95k | NEW | 100k | 0.95 |
|
| Replimune Group Call Call Option | 0.0 | $12k | -54% | 231k | 0.05 |
|
| Viking Therapeutics Call Call Option | 0.0 | $2.0k | NEW | 100k | 0.02 |
|
| Replimune Group Put Put Option | 0.0 | $0 | NEW | 265k | 0.00 |
|
| Vistagen Therapeutics Call Call Option | 0.0 | $0 | NEW | 493k | 0.00 |
|
| Rezolute Call Call Option | 0.0 | $0 | 263k | 0.00 |
|
Past Filings by Rosalind Advisors
SEC 13F filings are viewable for Rosalind Advisors going back to 2023
- Rosalind Advisors 2025 Q4 filed Feb. 12, 2026
- Rosalind Advisors 2025 Q3 filed Nov. 13, 2025
- Rosalind Advisors 2025 Q2 filed Aug. 14, 2025
- Rosalind Advisors 2025 Q1 filed May 14, 2025
- Rosalind Advisors 2024 Q4 restated filed Feb. 14, 2025
- Rosalind Advisors 2024 Q3 filed Oct. 30, 2024
- Rosalind Advisors 2024 Q2 filed July 12, 2024
- Rosalind Advisors 2024 Q1 filed April 25, 2024
- Rosalind Advisors 2023 Q4 filed Feb. 14, 2024